Remove Clinical Development Remove FDA Approval Remove Pharmaceuticals
article thumbnail

The science of ageing and restoring healthspan

Drug Target Review

Jerry has over 30 years of experience in the biopharmaceutical industry and has been involved in the discovery, clinical development, and global commercialisation of more than a dozen FDA-approved drugs with multiple successful exits. a commercial stage pharmaceutical company.

Science 145
article thumbnail

Metabolism of 2022 FDA approved small molecule drugs PART 1

Metabolite Tales Blog

Metabolism of 2022 FDA approved small molecule drugs – Part 1 Does CYP3A4 still rule? By Julia Shanu-Wilson It won’t come as much surprise to learn that of the 17 small molecules* approved by the FDA in 2022, CYP3A4 was the major player in drug metabolism. References Iversen et al., Front Pharmacol.,

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

CNS Pharmaceuticals Announces FDA Approval of IND Application for its Brain Cancer Drug Candidate Berubicin

The Pharma Data

17, 2020 /PRNewswire/ — CNS Pharmaceuticals, Inc. “Since becoming a public company, our clear focus has been on advancing the clinical development of Berubicin. About CNS Pharmaceuticals, Inc. SOURCE CNS Pharmaceuticals, Inc. .

article thumbnail

FDA Approves Oxlumo (lumasiran) for the Treatment of Primary Hyperoxaluria Type 1

The Pharma Data

FDA Approves Oxlumo (lumasiran) for the Treatment of Primary Hyperoxaluria Type 1. 24, 2020– Alnylam Pharmaceuticals, Inc. We are grateful to all the investigators, staff and patients who participated in the ILLUMINATE clinical studies, and to their families, caregivers and patient advocates. CAMBRIDGE, Mass.–(BUSINESS

article thumbnail

Standigm and SK Chemicals Repurpose FDA-approved Drug into Rheumatoid Arthritis Candidate and Apply for Patent through their Open Innovation Partnership

The Pharma Data

As the compound was already approved by the FDA for its original indication, the companies are expecting significant savings in cost and time associated with its pre- or clinical development for the new indication. This patent is just the beginning of many results expected from our extended collaboration.

article thumbnail

UNION therapeutics A/S receives FDA approval for IND of oral next generation PDE4-inhibitor (orismilast) for investigation in plaque psoriasis

The Pharma Data

He continues: “With the green light granted by the FDA to continue our clinical research, we are one step closer to offering psoriasis patients a novel, improved oral treatment option and thereby enhancing their quality of life. UNION is headquartered in Hellerup ( Denmark ) and is managed by an experienced international team.

article thumbnail

FDA approves Roche’s Evrysdi for use in babies under two months with spinal muscular atrophy (SMA)

The Pharma Data

.” Evrysdi is approved in 81 countries and the dossier is under review in a further 27 countries. More than 5,000 patients have now been treated worldwide with Evrysdi in clinical trials, compassionate use or real-world settings.